Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetanus toxoid-specific CD4+ T helper cells are a specialized population of memory T lymphocytes primed by tetanus toxoid (TT) vaccination [Expert Opinion on Biological Therapy, 2013]. These cells recognize TT-derived peptides presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells [Nature, 1985]. Upon activation, they proliferate and secrete cytokines like IFN-gamma and IL-2, which orchestrate adaptive immune responses [Nature Medicine, 2005]. In pharmaceutical development, they are essential for the efficacy of conjugate vaccines, providing T-cell help to B cells for antibody production against polysaccharides [Nature Reviews Immunology, 2009]. They also serve as a gold-standard recall antigen population in clinical assays to evaluate cellular immune function [Journal of Immunological Methods, 2021]. Furthermore, recent therapeutic strategies have explored using TT-specific CD4+ T cells to enhance anti-tumor immunity by pre-conditioning vaccination sites with tetanus toxoid to recruit these potent helper cells to the site of treatment [Nature, 2015]. Their presence and activity are key indicators of vaccine potency and individual immune competence. Therapeutic targeting of these cells primarily involves vaccination or the use of TT as a carrier protein. Safety concerns are generally limited to localized or systemic hypersensitivity reactions following re-exposure to the antigen. Overall, they represent a robust and predictable component of the human immune memory used extensively in both preventative and therapeutic medicine.
Activation of the T-cell receptor (TCR) complex by tetanus toxoid peptides presented on MHC Class II molecules, leading to cytokine secretion and B-cell help [Nature, 1985; Nature Medicine, 2005].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetanus toxoid-specific CD4+ T helper cells (TT-specific CD4+ T cells) (TT-specific CD4+ T cells).